ATIM-29. A PHASE 1 STUDY OF PF-06840003, AN ORAL INDOLE 2,3-DIOXYGENASE 1 (IDO1) INHIBITOR IN PATIENTS WITH MALIGNANT GLIOMAS

Por Reardon, David, Desjardins, Annick, Rixe, Olivier, Cloughesy, Timothy, Alekar, Shilpa, Gamelin, Erick, Williams, Jason, Meissen, John, Taylor, Carrie, Lassman, Andrew
Publicado no Neuro Oncol (2017)

First-in-human trial of an anti-5T4 antibody-monomethylauristatin conjugate, PF-06263507, in patients with advanced solid tumors

Por Shapiro, Geoffrey I., Vaishampayan, Ulka N., LoRusso, Patricia, Barton, Jeremy, Hua, Steven, Reich, Steven D., Shazer, Ronald, Taylor, Carrie T., Xuan, Dawei, Borghaei, Hossein
Publicado no Invest New Drugs (2017)

A randomized phase 1 pharmacokinetic trial comparing the potential biosimilar PF-05280014 with trastuzumab in healthy volunteers (REFLECTIONS B327-01)(1)

Por Yin, Donghua, Barker, Kerry B, Li, Ruifeng, Meng, Xu, Reich, Steven D, Ricart, Alejandro D, Rudin, Dan, Taylor, Carrie T, Zacharchuk, Charles M, Hansson, Arne G
Publicado no Br J Clin Pharmacol (2014)